Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.77−0.09 (-2.33%)
Close on Nov 18, 2026Market cap $184.32MP/E –Yield –
Artiva Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Artiva Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$96.15M. For fiscal 2025 it was -$89.81M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$89.81M | – |
| FY2024 | Dec 31, 2024 | -$67.28M | – |
| FY2023 | Dec 31, 2023 | -$30.67M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.34M | -269.6% |
| Q2 FY2024 | Jun 30, 2024 | -$16.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.97M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.82M | – |
See a number that looks wrong?